Yukari Yamada

Abstract 4784: TAS0286/HM05, a novel highly selective RET inhibitor, prominently inhibits various RET defective tumor growth

Masanori Kato, Y. Iwasawa, K. Matsuo, 2018, Experimental and Molecular Therapeutics.

Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2′-deoxy-5-fluorouridine into DNA

H. Okabe, K. Matsuo, H. Ueno, 2015, International journal of oncology.

Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

M. Ladanyi, R. Somwar, E. de Stanchina, 2023, Nature Cancer.

Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models

A. Fujioka, F. Nakagawa, H. Okabe, 2014, Oncology reports.